Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1375 of 1631 entries
View as:

A Follow-up Physician Survey to Evaluate Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe

Phase: N/A Priority: Normal
NCT ID: NCT04067583 Org: User:
Start: 10/08/19 End: 04/23/20 Due: 04/23/21

A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles

Phase: N/A Priority: Normal
NCT ID: NCT00631124 Org: User:
Start: 02/29/08 End: 12/31/08 Due: 12/31/09

Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan

Phase: N/A Priority: Normal
NCT ID: NCT00969449 Org: User:
Start: 04/30/09 End: 05/31/09 Due: 05/31/10

Study to Assess the Safety, Tolerability, Effects on the Body, Absorption, Distribution and Elimination of 25 mg BAY2433334 in Renal Impairment Including Renal Replacement Therapy ("Dialysis")

Phase: N/A Priority: Normal
NCT ID: NCT04510987 Org: User:
Start: 08/12/20 End: 12/15/21 Due: 12/15/22

Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01335256 Org: User:
Start: 12/31/10 End: 09/30/11 Due: 09/30/12

Sun Protection Factor Assay (344/2016)

Phase: N/A Priority: Normal
NCT ID: NCT02995161 Org: User:
Start: 12/30/16 End: 01/04/17 Due: 01/04/18

Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)

Phase: N/A Priority: Normal
NCT ID: NCT01679587 Org: User:
Start: 09/30/12 End: 07/31/13 Due: 07/31/14

A Clinical Trial to Compare Safety and Effectiveness for Relieving Tenderness of 10% Naproxen Gel vs. a 2.32% Diclofenac Diethylamine Gel in the Treatment of Strains and Bruises of the Legs.

Phase: N/A Priority: Normal
NCT ID: NCT05026320 Org: User:
Start: 08/08/21 End: 12/20/21 Due: 12/20/22

Sun Protection Factor (SPF) - Static and Water Resistant Assay

Phase: N/A Priority: Normal
NCT ID: NCT02857738 Org: User:
Start: 05/26/15 End: 06/10/15 Due: 06/10/16

Study to Find Out the Optimal Dose of Caffeine in the Combination Tablet of Naproxen Sodium and Caffeine in Patients Experiencing Moderate to Severe Pain After Having Wisdom Teeth Removed

Phase: N/A Priority: Normal
NCT ID: NCT04132336 Org: User:
Start: 11/12/19 End: 03/03/20 Due: 03/03/21

Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium

Phase: N/A Priority: Normal
NCT ID: NCT00941057 Org: User:
Start: 09/30/09 End: 01/31/10 Due: 01/31/11

Mass Balance Study of [14C]-NT-814 Oral Suspension in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04654897 Org: User:
Start: 09/30/20 End: 10/29/20 Due: 10/29/21

Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)

Phase: N/A Priority: Normal
NCT ID: NCT02191137 Org: User:
Start: 09/23/14 End: 07/16/16 Due: 07/16/17

An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study

Phase: N/A Priority: Normal
NCT ID: NCT00402467 Org: User:
Start: 02/29/04 End: 11/30/04 Due: 11/30/05

Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)

Phase: N/A Priority: Normal
NCT ID: NCT00494299 Org: User:
Start: 04/30/06 End: 11/30/10 Due: 11/30/11

Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single and Multiple Oral BAY1101042 Tablet Doses in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03252002 Org: User:
Start: 08/16/17 End: 07/24/19 Due: 07/24/20

A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT06222697 Org: User:
Start: 01/24/24 End: 06/30/26 Due: 06/30/27

An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting

Phase: N/A Priority: Normal
NCT ID: NCT06148935 Org: User:
Start: 11/30/23 End: 09/30/27 Due: 09/30/28

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00306137 Org: User:
Start: 12/31/05 End: 03/31/07 Due: 03/31/08

Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

Phase: N/A Priority: Normal
NCT ID: NCT00694850 Org: User:
Start: 08/02/08 End: 10/01/25 Due: 10/01/26

A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions

Phase: N/A Priority: Normal
NCT ID: NCT05666518 Org: User:
Start: 08/31/22 End: 12/31/28 Due: 12/31/29

Non-interventional Study on Oral Contraception Not Containing Ethinylestradiol (EE) to Assess Continuation Rates and Satisfaction

Phase: N/A Priority: Normal
NCT ID: NCT01200186 Org: User:
Start: 10/31/10 End: 10/31/14 Due: 10/31/15

Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study

Phase: N/A Priority: Normal
NCT ID: NCT02991131 Org: User:
Start: 12/17/16 End: 11/21/18 Due: 11/21/19

Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Phase: N/A Priority: Normal
NCT ID: NCT01516762 Org: User:
Start: - End: - Due: -

A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06348888 Org: User:
Start: 04/10/24 End: 06/12/24 Due: 06/12/25